Incremental Prognostic Value of Biomarkers in PARADIGM-HF
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2887 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Kirsty McDowell und 12 weiteren Autor:innen. Beteiligte Einrichtung: BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Heart Failure. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: British Heart Foundation, Novartis Pharma.
Abstract (Originalsprache)
Aims
It is uncertain how much candidate biomarkers improve risk prediction when added to comprehensive models including routinely collected clinical and laboratory variables in heart failure. Methods and results Aldosterone, cystatin C, high-sensitivity troponin T (hs-TnT), galectin-3, growth differentiation factor-15 (GDF-15), kidney injury molecule-1, matrix metalloproteinase-2 and -9, soluble suppression of tumourigenicity-2, tissue inhibitor of metalloproteinase-1 (TIMP-1) and urinary albumin to creatinine ratio were measured in 1559 of PARADIGM-HF participants. We tested whether these biomarkers, individually or collectively, improved the performance of the PREDICT-HF prognostic model, which includes clinical, routine laboratory, and natriuretic peptide data, for the primary endpoint and cardiovascular and all-cause mortality. The mean age of participants was 67.3 ± 9.9 years, 1254 (80.4%) were men and 1103 (71%) were in New York Heart Association class II. During a mean follow-up of 30.7 months, 300 patients experienced the primary outcome and 197 died. Added individually, only four biomarkers were independently associated with all outcomes: hs-TnT, GDF-15, cystatin C and TIMP-1. When all biomarkers were added simultaneously to the PREDICT-HF models, only hs-TnT remained an independent predictor of all three endpoints. GDF-15 also remained predictive of the primary endpoint; TIMP-1 was the only other predictor of both cardiovascular and all-cause mortality. Individually or in combination, these biomarkers did not lead to significant improvements in discrimination or reclassification.
Conclusions
None of the biomarkers studied individually or collectively led to a meaningful improvement in the prediction of outcomes over what is provided by clinical, routine laboratory, and natriuretic peptide variables.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
- Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.
- Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
- National Heart and Lung Institute, Imperial College London, London, UK.
Förderung
- British Heart Foundation
- Novartis Pharma
Zitieren
APA
McDowell, K., Campbell, R., Simpson, J., Cunningham, J. W., Desai, A. S., Jhund, P. S., Lefkowitz, M. P., Rouleau, J. L., Swedberg, K., Zile, M. R., Solomon, S. D., Packer, M., & McMurray, J. J. V. (2023). Incremental Prognostic Value of Biomarkers in PARADIGM-HF. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2887
Vancouver
McDowell K, Campbell R, Simpson J, Cunningham JW, Desai AS, Jhund PS, et al. Incremental Prognostic Value of Biomarkers in PARADIGM-HF. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2887
BibTeX
@article{McDowell2023,
author = {McDowell, Kirsty and Campbell, Ross and Simpson, Joanne and Cunningham, Jonathan W and Desai, Akshay S and Jhund, Pardeep S and Lefkowitz, Martin P and Rouleau, Jean L and Swedberg, Karl and Zile, Michael R and Solomon, Scott D and Packer, Milton and McMurray, John J V},
title = {Incremental Prognostic Value of Biomarkers in PARADIGM-HF},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2887}
}
EUVIMED